Akero Therapeutics — Technical Presentation (October 2023)
25 slides from Akero Therapeutics's technical presentation, Oct 10, 2023
Slide 1: Phase 2b SYMMETRY Readout
Phase 2b SYMMETRY Readout October 10, 2023 Exhibit 99.2
Slide 2: Safe Harbor and Legal Disclaimers
Safe Harbor and Legal Disclaimers ©2023 AKERO THERAPEUTICS. This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operat
Slide 3: High Risk of Mortality Associated with Cirrhosis Due to NASH
High Risk of Mortality Associated with Cirrhosis Due to NASH ©2023 AKERO THERAPEUTICS. Survival Free of Liver Transplantation Follow-up (years) Cumulative Survival (%) Angulo, P et al. (2015) Gastroenterology 149:389-397 P<0.001 F4 50% ~50% 5-year mortality without liver transplant for F4 patients 4
Slide 4: Landscape for Cirrhosis Due to NASH: Placebo-Corrected Fibrosis Improvement
Landscape for Cirrhosis Due to NASH: Placebo-Corrected Fibrosis Improvement With No Worsening of NASH ©2023 AKERO THERAPEUTICS. Aldafermin 48 Wks / Ph2b Discontinued 15% FGF19 (n=42) 1mg 3mg (n=55) 8% 6% Selonsertib 48 Wks / Ph3 Discontinued 13% ASK-1 Peg-FGF21 Pegbelfermin 48 Wks / Ph2b Discontinue
Slide 5: Landscape for Cirrhosis Due to NASH: Placebo-Corrected NASH Resolution
Landscape for Cirrhosis Due to NASH: Placebo-Corrected NASH Resolution ©2023 AKERO THERAPEUTICS. Selonsertib 48 Wks / Ph3 Discontinued 4% ASK-1 Peg-FGF21 Pegbelfermin 48 Wks / Ph2b Discontinued 0% (n=351) (n=354) 6mg 18mg (n=37) 20mg (n=39) 40mg Semaglutide 48 Wks / Ph2b Active 21% GLP-1 (n=47) 13%
Slide 6: SYMMETRY Trial Design: Cirrhosis Due to NASH (F4)
SYMMETRY Trial Design: Cirrhosis Due to NASH (F4) ©2023 AKERO THERAPEUTICS. EFX 28mg (N=57) Placebo (N=61) 36 Weeks EFX 50mg (N=63) Placebo EFX 28mg 60-Week Long-Term Follow-Up Screening Randomization Phase 2b Key Inclusion Criteria1 F4 NASH T2D or 2 of 4 components of metabolic syndrome Phase 2b Pr
Slide 7: Patient Disposition & Key Analysis Sets
Week 36 Patient Disposition & Key Analysis Sets ©2023 AKERO THERAPEUTICS. Randomized (N=182) Completed Week 36 (N=155) Biopsies Collected (N=153) Randomized Not Dosed EFX (N=1) Discontinued Prior to Week 36 (N=26) Dosed (N=181) Due to AEs (15) EFX (N=13) Placebo (N=2) Other (11) EFX (N=9) Placebo (N
Slide 8: Baseline Demographics
Baseline Demographics ©2023 AKERO THERAPEUTICS. Parameter (Mean) Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) Age (Years) 61 62 59 Sex (% Female) 62 68 70 Definitive NASH (%) / Cryptogenic Cirrhosis (%) 74 / 26 79 / 21 83 / 17 Enhanced Liver Fibrosis (ELF) Score 10.4 10.6 10.5 Pro-C3 (μg/L) (Gener
Slide 9: Consensus Reading of Biopsies: Rigorous Approach to Histopathology
Consensus Reading of Biopsies: Rigorous Approach to Histopathology Based on FDA Input to Minimize Variability ©2023 AKERO THERAPEUTICS. Different Scores Slides Prepared From Tissue Samples Score 1 Score 2 Same Score Consensus Score Adjudicated Score No Consensus Consensus Meeting Final Score QC’d an
Slide 10: Trend to Improvement for Primary Endpoint
Trend to Improvement for Primary Endpoint (≥1 Stage Improvement in Fibrosis and No Worsening of NASH) ©2023 AKERO THERAPEUTICS. Fibrosis Improvement ≥1 Stage Without Worsening of NASH1 at Week 362 Source Data: Liver Biopsy Analysis Set; Topline preliminary data 22% 14% 24% 1 Per FDA guidance, this e
Slide 11: Statistically Significant Improvement on NASH Resolution for Both Doses
Statistically Significant Improvement on NASH Resolution for Both Doses ©2023 AKERO THERAPEUTICS. Source Data: Liver Biopsy Analysis Set (definitive NASH only); Topline preliminary data 1 Per FDA guidance, resolution of steatohepatitis is defined as “absent fatty liver disease or isolated or simple
Slide 12: Combined Histological Endpoint: Fibrosis Improvement AND NASH Resolution
Combined Histological Endpoint ©2023 AKERO THERAPEUTICS. Fibrosis Improvement ≥1 Stage AND NASH Resolution1 at Week 36 Source Data: Liver Biopsy Analysis Set (definitive NASH only); Topline preliminary data 1 Per FDA guidance, this endpoint is defined as: “Both resolution of steatohepatitis and impr
Slide 13: Landscape for Cirrhosis Due to NASH: Placebo-Corrected Fibrosis Improvement
Aldafermin 48 Wks / Ph2b Discontinued 15% FGF19 (n=42) 1mg 3mg (n=55) 8% 6% Landscape for Cirrhosis Due to NASH: Placebo-Corrected Fibrosis Improvement With No Worsening of NASH ©2023 AKERO THERAPEUTICS. Selonsertib 48 Wks / Ph3 Discontinued 13% ASK-1 Peg-FGF21 Pegbelfermin 48 Wks / Ph2b Discontinue
Slide 14: Landscape for Cirrhosis Due to NASH: Placebo-Corrected NASH Resolution
Landscape for Cirrhosis Due to NASH: Placebo-Corrected NASH Resolution Note: These data are derived from different clinical trials at different points in time, with differences in trial design and patient populations. No head-to-head clinical trials have been conducted. ©2023 AKERO THERAPEUTICS. Sel
Slide 15: Evidence of Anti-Fibrotic Activity: Analysis of ELF Score and Components
ELF Component: P3NP (ug/L)2 *** -3.5 *** -0.4 EFX 50mg N=51 Placebo N=58 EFX 28mg N=47 *** -3.5 *** *** p<0.001, versus placebo (MMRM) 2 Procollagen 3 N-Terminal Peptide ELF Component: TIMP1 (ug/L)1 ** p<0.01, *** p<0.001, versus placebo (MMRM) ** -32.2 ** +0.5 *** -38.1 *** EFX 50mg N=51 Placebo N=
Slide 16: Additional Non-Invasive Fibrosis Markers
Additional Non-Invasive Fibrosis Markers ©2023 AKERO THERAPEUTICS. LS Mean Change From Baseline to Week 36 1 Mixed Model Repeated Measures; 2 Measured by FibroScan Pro-C3 (µg/L): Generation 2 ELISA EFX 50mg N=50 Placebo N=58 EFX 28mg N=47 FAST Score ** p<0.01, *** p<0.001, versus placebo (MMRM1) **
Slide 17: Early and Sustained Improvements in Markers of Liver Injury
-13 U/L -11 U/L -5 U/L ** *** ** ** ** ** * * ** ** ** -10 U/L -12 U/L -3 U/L *** *** *** *** *** *** *** *** *** *** ** * ** * ** *** Early and Sustained Statistically Significant Improvements in Markers of Liver Injury ©2023 AKERO THERAPEUTICS. Source Data: Full Analysis Set; Topline preliminary d
Slide 18: Safety & Tolerability Summary
Safety & Tolerability Summary ©2023 AKERO THERAPEUTICS. TEAE Overview Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) TEAE Leading to Death 1 (2%) a 0 (0%) 0 (0%) Treatment-Emergent Serious Adverse Event (SAE) b 6 (10%) 9 (16%) 6 (10%) Drug-related TEAE Leading to Discontinuation 1 (2%) 3 (5%) 8 (13%
Slide 19: Safety & Tolerability (continued)
Safety & Tolerability (continued) ©2023 AKERO THERAPEUTICS. Most Frequent (≥15%) Drug-Related TEAEs Placebo (N=61) EFX 28mg (N=57) EFX 50mg (N=63) Diarrhea 9 (15%) 10 (18%) 19 (30%) Nausea 7 (12%) 11 (19%) 18 (29%) Increased Appetite 3 (5%) 7 (12%) 17 (27%) Injection Site Erythema 5 (8%) 8 (14%) 13
Slide 20: Statistically Significant Improvements Observed in Insulin Sensitivity
Statistically Significant Improvements Observed in Insulin Sensitivity ©2023 AKERO THERAPEUTICS. LS Mean Change From Baseline to Week 36 EFX 50mg N=48 Placebo N=59 EFX 28mg N=47 EFX 50mg N=50 Placebo N=58 EFX 28mg N=47 EFX 50mg N=48 Placebo N=59 EFX 28mg N=47 Source Data: Full Analysis Set; Topline
Slide 21: Statistically Significant Improvements Observed in Lipoprotein Profile
Non-HDL Cholesterol ††† -10 ††† -3 ** -15 ** EFX 50mg N=50 Placebo N=58 EFX 28mg N=47 LDL Cholesterol -5 -1 ††† -10 ††† EFX 50mg N=48 Placebo N=58 EFX 28mg N=47 HDL Cholesterol *** p<0.001, versus placebo (MMRM) Statistically Significant Improvements Observed in Lipoprotein Profile ©2023 AKERO THERA
Slide 22: Statistically Significant Increases Observed in Adiponectin
Statistically Significant Increases Observed in Adiponectin: PD Marker for EFX’s Action on Adipose Tissue ©2023 AKERO THERAPEUTICS. Adiponectin, LS Mean Percent Change From Baseline to Week 36 *** p<0.001, versus placebo (MMRM) *** +114 *** +9 *** +92 *** EFX 50mg N=50 Placebo N=58 EFX 28mg N=46
Slide 23: Trend Toward Weight Loss for 50mg EFX Dose Group
Trend Toward Weight Loss for 50mg EFX Dose Group ©2023 AKERO THERAPEUTICS. Source Data: Full Analysis Set; Topline preliminary data Body Weight, LS Mean Percent Change From Baseline to Week 36 -0.8 -0.8 † -1.4 † EFX 50mg N=51 Placebo N=58 EFX 28mg N=47 † p<0.05 versus baseline (MMRM)
Slide 24: Looking Ahead
Looking Ahead ©2023 AKERO THERAPEUTICS. Three Planned Parallel Randomized, Placebo-Controlled Clinical Trials Biopsy confirmed F2-F3 NASH Primary endpoint: ≥ 1-stage fibrosis improvement AND resolution of NASH 28 and 50mg EFX Non-invasively diagnosed NASH/NAFLD Primary endpoint: safety & tolerabilit
Slide 25: Akero Therapeutics
AKERO THERAPEUTICS 601 Gateway Boulevard Suite 350 South San Francisco, CA 94080
Akero Therapeutics — Technical Presentation (October 2023) on 6ix